Practical Liposomal Formulation for Taxanes with Polyethoxylated Castor Oil and Ethanol with Complete Encapsulation Efficiency and High Loading Efficiency
暂无分享,去创建一个
M. Seno | H. Hamada | Ayano Satoh | Tetsuya Ito | T. Kasai | Tsukasa Shigehiro | Arun Vaidyanath | Akifumi Mizutani | H. Murakami | Yuhki Seno | T. Mandai | Akimasa Seno | A. C. Khayrani | S. Saito | Kazumasa Jinno | Junko Masuda
[1] Wahid Khan,et al. Liposomal Formulations in Clinical Use: An Updated Review , 2017, Pharmaceutics.
[2] P. Kantoff,et al. Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.
[3] V. Adam,et al. Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes , 2016, Scientific Reports.
[4] D. Salomon,et al. Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient , 2016, Journal of microencapsulation.
[5] Soon-Seok Hong,et al. Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. , 2015, International journal of pharmaceutics.
[6] V. Adam,et al. Modulation of Induced Cytotoxicity of Doxorubicin by Using Apoferritin and Liposomal Cages , 2014, International journal of molecular sciences.
[7] D. Salomon,et al. Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation , 2014, PloS one.
[8] Peeyush N. Goel,et al. Anti-neuropilin 1 antibody Fab′ fragment conjugated liposomal docetaxel for active targeting of tumours , 2014, Journal of drug targeting.
[9] D. Salomon,et al. Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells , 2013, Journal of Cancer.
[10] Jaroslav Turánek,et al. Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[11] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[12] M. Seno,et al. Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand , 2011, Journal of cellular and molecular medicine.
[13] Kazuo Maruyama,et al. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.
[14] Hsiang-Fa Liang,et al. A Liposomal Formulation Able to Incorporate a High Content of Paclitaxel and Exert Promising Anticancer Effect , 2010, Journal of drug delivery.
[15] D. Salomon,et al. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. , 2010, International journal of pharmaceutics.
[16] J. Turánek,et al. Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect. , 2010, Journal of pharmaceutical sciences.
[17] Leaf Huang,et al. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. , 2009, Biochimica et biophysica acta.
[18] H. Shmeeda,et al. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[19] T. Yang,et al. Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.
[20] A. Martin,et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines , 2007, Cell proliferation.
[21] Dae-Duk Kim,et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[22] Dae-Duk Kim,et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. , 2007, International journal of pharmaceutics.
[23] R. Govindan,et al. Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Hong Liu,et al. Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel. , 2005, World journal of gastroenterology.
[25] F. Sarkar,et al. Epidermal growth factor receptor (EGFR)–related protein inhibits multiple members of the EGFR family in colon and breast cancer cells , 2005, Molecular Cancer Therapeutics.
[26] D. Weaver,et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells , 2004, International journal of cancer.
[27] F. Dosio,et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[28] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[29] K. Hara,et al. Synthesis and Biological Evaluation of Water Soluble Taxoids Bearing Sugar Moieties , 2001 .
[30] F. Dosio,et al. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[31] P. Cullis,et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.
[32] Lawrence Mayer,et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel , 1997, Anti-cancer drugs.
[33] E. Moase,et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.
[34] Philip R. Cohen,et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). , 1993, Cancer treatment reviews.
[35] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[36] M. D’Incalci,et al. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[38] 山本 祐司. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts , 2011 .
[39] M. Bissery,et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®) , 2007, Investigational New Drugs.
[40] T. Andresen,et al. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.
[41] Lyndsay Harris,et al. Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.